ENVIRONMENTAL, SOCIALAND GOVERNANCE REPORTMARCH 2023

CONTENTS
Who We Are

2

AlloCAR T ™ Products:
Improving Access to Cell Therapy

3

Valuing Our People

6

Our Allogene Community

7

Our One Allogene Culture

8

Cancer Doesn’t Discriminate and Neither Do We

10

Staying Connected and Informed

12

Safety in the Workplace

13

Recruiting, Developing and Retaining Talent

15

Compensation & Benefits

16

Career Development

18

Spot Recognition through Allogene’s Gratitude Lab

18

Taking a Stand

18

Prioritizing Environmental Sustainability

19

The Facility of the Future: Cell Forge 1

21

Current Initiatives to Reduce Environmental Impact

22

Our Focus for the Future

22

Pursuing the Highest Ethical Standards

23

Allogene’s Board and Corporate Governance23

Business Ethics and Human Rights

24

Clinical Trials

26

Product Quality and Patient Safety27

Supply Chain and Partners

27

Managing Cybersecurity Risk

28

ALLOGENE ENVIRONMENTAL, SOCIAL AND GOVERNANCE REPORT | 1

FROM OUR CEO
Great leaders throughout history have embraced being the face of change,

But this must be done in parallel as we prioritize sustainability and holdaccepting the challenge and opportunity to make a difference in the world. Yetourselves to high ethical standards to ensure we are good corporate citizens

this also comes with an incredible sense of responsibility. Last year, we took greatalong the way.

pride in being one of the first companies of our size and in our industry to publish
an ESG report. As we publish our second ESG report, we continue to embrace
being the face of change as we have initiated the industry’s first potentiallypivotal Phase 2 allogeneic CAR T trial and are the first company to demonstrate
proof-of-concept for an AlloCAR T™ product in multiple diseases, including thepotential for an AlloCAR T™ product in the treatment of solid tumors.
There currently exists a growing access bottleneck in cell therapy, one in which
patients are placed on waitlists as their disease progresses and physicians areforced to make difficult decisions about which of their patients should receive
treatment. The challenges faced by our nascent industry are just beginning as
demand grows for currently approved autologous CAR T therapies. Autologous

Our Allogene community is critical to our success, and efforts to cultivate abest-in-class workforce are once again at the core of our sustainability activities.
In 2022 we appointed a Chief People Officer, demonstrating our commitment
to retaining and developing our incredible teams as we work together to bringour products to patients. Our One Allogene culture is core to everything we doand striving to save the lives of patients with cancer remains our north star.
While this year begins our 5th year as a company, our work represents what
could be a lifetime of hope for many. I am incredibly proud of how our teams aretaking steps to limit our impact on the environment, prioritize the people who
make our work possible, and govern Allogene to align with key stakeholders.

CAR T requires a bespoke manufacturing process and complex supply chain

We are proud to be the face of change and make a positive impact on societythat limits the number of patients who may potentially benefit from the therapy.

as we work to revolutionize cancer therapy and make AlloCAR T™ products a

The next revolution is a seismic shift, evolving CAR T from a therapy to an

reality for patients.

off-the-shelf product that can be delivered on-demand, reliably and at scale– democratizing cell therapy, increasing access, and bringing new hope toSincerely,

patients and the physicians who treat them.
Our Allogene community works hard to be the face of change with a boldDavid Chang, M.D., Ph.D.

mission – to lead the field in delivering the first allogeneic CAR T products to

President, Chief Executive Officer

patients with blood cancers and solid tumors.

and Co-FounderALLOGENE ENVIRONMENTAL, SOCIAL AND GOVERNANCE REPORT | 2

WHO WE ARE
Allogene Therapeutics, with headquarters in South San Francisco, is a clinical-stage

At Allogene, our mission is tobiotechnology company pioneering the development of allogeneic chimeric antigen

create and lead the next

significant experience in cell therapy, we are developing a pipeline of “off-the-shelf”

revolution in cancer treatment
by delivering to patients thefirst AlloCAR T™ products forblood cancers and solid
tumors. As a team, working
together, we believe we canrevolutionize cancer treatment
by making AlloCAR T™
products a reality for patients.

receptor T cell (AlloCAR T ™) products for cancer. Led by a management team withCAR T product candidates with the goal of delivering CAR T on-demand, morereliably, and at greater scale to more patients.
This mosaic is hung in the lobby of ourheadquarters. It is made up of photos
submitted by our employees – photos that
represent their motivations for working
at Allogene to deliver the first AlloCAR T ™
products to patients. Through our mosaic
and onsite visual media, our team isreminded of the importance of creating acell therapy that can one day be available
to all patients in need.

ALLOGENE ENVIRONMENTAL, SOCIAL AND GOVERNANCE REPORT | 3

AlloCAR T PRODUCTS:
IMPROVING ACCESS TO CELL THERAPY™

Oncology is undergoing a transformation.
Innovative new technologies, including cell-based

Recent Survey Unveils Real-World Access Challenges

therapies designed to eradicate cancer, are rapidly
emerging. But to realize the full potential of thisinnovation, we must democratize access. This
includes making it easier to deliver the therapies
that hold the promise of curative potential andsavings to the overall health care system.
That’s the promise of AlloCAR T products.
™

At Allogene, we are building upon the first wave
of innovation in cell therapy: autologous CAR T
therapies that arm cells from an individual’s own
immune system with cancer-killing technology.

Of eligible CAR T patients,

12%

82%

receive treatment
within one month;agree that CAR T therapies have changed
how they manage aggressive cancers.

~40%

Extensive wait times and manufacturing
limitations keep many eligible patientsfrom receiving treatment – even in
high-volume centers.

wait 3–6+ months
to receive
treatment

Autologous CAR T was a major step forward forpatients with late-stage blood cancers. However,engineering immune cells from each individual
For eligible patients,

patient is not always possible, and even when it
is, the process is complicated and lengthy.

2022 Survey sponsored by Allogene and conducted by anindependent third-party research organization of 50
U.S.-based hematologist-oncologists, physician assistants,
nurse practitioners, and registered nurses from academic
centers with CAR T therapy capabilities

50%

of eligible patients who can wait for
manufacturing receive an autologous
CAR T therapy

disease progression
manufacturing capacity
andcomorbidities

were the top reasons for not receiving CAR T.

ALLOGENE ENVIRONMENTAL, SOCIAL AND GOVERNANCE REPORT | 4

AlloCAR T ™ PRODUCTS:
IMPROVING ACCESS TO CELL THERAPY

Allogene CAR T products have the potential to treat dramatically more

As a leader in the field, we have faced and expect to face many challenges

patients across more cancer types, faster and with fewer limitations thanassociated with bringing allogeneic CAR T products to patients. We takeautologous CAR T therapies.

pride in taking the lead, expanding boundaries, building partnerships andRather than using a patients’ own cells as starting material, allogeneic
CAR T involves using donor cells from healthy volunteers that can beengineered at scale for use in a broad population of unrelated patients.
The process includes modifying the cells to reduce the risk ofgraft-versus-host disease as well as to create a window of persistencethat may enable allogeneic CAR T cells to expand and eradicate cancer
cells in patients. Benefits include:• Reduced complexity for patients and physicians due to the “off-the-shelf”
nature of treatment.
• Scalable manufacturing yielding the opportunity to treat many
more patients.
• Faster time to treatment given the potential for on-demand treatment.
• Potential to engineer novel functionality into cells, providing the ability
to possibly enhance efficacy, including in difficult to treat solid tumors.
• One-time dosing with greatly reduced inconvenience and cost relative tocontinuous treatments.

revolutionizing the future of cancer immunotherapy in order to bring newhope to millions of patients suffering from cancer around the world.

ALLOGENE ENVIRONMENTAL, SOCIAL AND GOVERNANCE REPORT | 5

AlloCAR T ™ PRODUCTS:
IMPROVING ACCESS TO CELL THERAPY

Autologous CAR T therapies face great hurdles to adoption in other partsof the world, which is why Allogene formed a joint venture with Overland
Pharmaceuticals – Allogene Overland Biopharm – in China, where the175+

patients treated in Phase 1
clinical trials with AlloCAR T
product candidates

Advancing2

population is large, diverse and geographically disperse. The joint venture
is dedicated to accelerating the global development of AlloCAR T ™
products, increasing access to CAR T, for patients with hematologic
malignancies and solid tumors in China and other Asian Pacific territories.

potentially Phase 2
pivotal trials

100+
2–5
days:

Median time toinitiate treatment

100%

of patients received
AlloCAR T products
manufactured andreleased per productspecifications

patients may betreated froma single
manufacturing run
at scale6

foundational
platform
technologies

13

pre-clinicaltargets

ALLOGENE ENVIRONMENTAL, SOCIAL AND GOVERNANCE REPORT | 6

VALUING OUR PEOPLE

ALLOGENE ENVIRONMENTAL, SOCIAL AND GOVERNANCE REPORT | 7

VALUING OUR PEOPLE

Our Allogene Community

Total
employees

are engaged in research, development

77% and technical operations>99% full-time

52%

self-reported
as women
DIRECTOR-LEVELAND ABOVE

Ethnic or racial minorities

EDUCATION BACKGROUND

as defined in the United States
ALL COMPANYDIRECTOR-LEVEL AND ABOVE

67%

48%

Asian

45%
self-reported as women52%

Black orAfrican American

37%

Hispanic or Latino

7%

As of February 1, 2023

7% 1%

Other minority groups or
two or more races

2%
4% 5%

81

employees hold Ph.D.
and/or M.D. degrees

ALLOGENE ENVIRONMENTAL, SOCIAL AND GOVERNANCE REPORT | 8

VALUING OUR PEOPLE

Our One Allogene Culture
At Allogene, we have an experienced team of people singularly focused

In November 2022, with the assistance of aon transforming the treatment of cancer. We come together with thethird-party service provider, we conductedshared goal of making a life-changing difference for patients, and wea company-wide employee engagement

embrace diversity of experience, backgrounds and thought because wesurvey. 92% of employees participated,

are confident that these differences support our mission to create andsurpassing the service provider’s standard

lead the next revolution in cancer therapy.

benchmark of 80% participation rate. Survey

In 2022, Allogene was recognized as a Best Place to Work by both the
San Francisco Business Times and BioSpace. We attribute these awards
to the significant effort we’ve put into fostering our One Allogene culture,
which we formally established in 2021.
Since formally defining our culture, One Allogene has permeated throughAllogene in many ways, including our diversity, equity and inclusion (DEI)
initiatives, recruitment, new hire onboarding, manager and interview
training, performance management, peer recognition, and wellness
programs. To promote cultural alignment, a group of cross-functional“employee ambassadors” find ways to connect teams to our culture,advance team building activities, and provide recognition opportunities.
Our culture continues to evolve based on company growth, business
need, industry changes and employee feedback. We encourage candid
employee feedback to ambassadors, anonymous submissions to our
One Allogene suggestion box, and participation in employee surveys.

results demonstrated that employees are extremely committed to thesuccess of the company and are driven by Allogene’s mission.

ALLOGENE ENVIRONMENTAL, SOCIAL AND GOVERNANCE REPORT | 9

VALUING OUR PEOPLE

2022 Employee Engagement Survey Company Scorecard
True to our One Allogene behavior, “Be transparent,” survey results wereshared with all employees at a Town Hall meeting, and the 2023 employee
engagement plan will be influenced by our findings.

I really care about
the success of
this company.

I am proud of
the work that I do
in connection to
Allogene’s mission
to create and leadthe next revolution
in cancer therapy.

98.0

94.0

Company score is the average of positive responses and negative responses.

My manager
wants to seeme succeed.

My job feels
important to me
because it is aligned
to the vision andmission of
the company.

I find my work
to be apositive challenge.

88.0

88.0

87.0

ALLOGENE ENVIRONMENTAL, SOCIAL AND GOVERNANCE REPORT | 10

VALUING OUR PEOPLE
DEI COMMITTEE MISSION STATEMENT

Cancer Doesn’t Discriminate, and Neither Do We

Cancer doesn’t care about your culture, race,

Since our inception, we have embraced DEI and we strive every day to

its treatment. We are committed to defeating

create an inclusive environment.

cancer by leveraging the power of diversity

Our DEI initiatives are applicable to our practices and policies, such as
those on recruitment, compensation, and professional development.

ethnicity, gender or identity. Neither should

to unlock the best in each of us.
We foster an inclusive environment throughrespect, collaboration, and open communication
with the goal of effecting change. Employee recruitment,

We are focused on continuing to augment the diversity of ourinternships and mentorships are designed to create a stronger andworkforce and increase opportunities to underrepresented

better Allogene that delivers life-changing products for patients.

minorities by:• Participating in diversity-focused career fairs that promote theinclusion of multi-ethnic or diverse communities of professionals.

• Offering added incentives for employees to refer candidates fromunderrepresented groups.

• Providing guidance and training on DEI best practices for

We continue to progress an inclusive work environmentthat encourages:• Respectful communication and cooperation between all employees.

interviewers and utilizing diverse interview panels to encourage• Valuing and soliciting input, feedback and opinions.

consideration of candidates from underrepresented groups. We• Teamwork and employee participation, permitting a full

also now require that all Allogene recruiters be trained as Certified
Diversity and Inclusion Recruiters.

representation of perspectives.

• Employer and employee contributions to the communities we serve
to promote a greater understanding and respect for diversity.

ALLOGENE ENVIRONMENTAL, SOCIAL AND GOVERNANCE REPORT | 11

VALUING OUR PEOPLE

To champion our efforts in this area, in 2020 we formed a DEI Committee,
which is comprised of employees of various levels, departments andbackgrounds and is sponsored by our Chief Communications Officer. The DEI
Committee formalized a mission statement and advanced a DEI policy toestablish Allogene’s commitment to diversity, equity, and inclusion and toensure our employees are aware of their obligations to adhere to our policy.
Pursuant to our DEI policy, all employees are encouraged to attend andcomplete annual diversity awareness training and new employees are
required to take a training on managing unconscious bias.
The DEI Committee continually works to identify gaps, respond to employee
feedback, and present suggestions on our practices and policies. These
actions are designed to encourage and provide for an environment in which
all employees feel included and empowered to achieve their best.

T he DEI Committee aims to increase employee awareness ofdifferent cultures, behaviors, experiences and backgrounds by:• Inviting expert external speakers to educate our team on topics such as“The I in DEI” and “How to Become an Effective Ally.”• Expanding to new diversity topics, such as neurodiversity based uponemerging new research and employee requests.
• Hosting our “Let’s Talk” series of small group discussions aboutprominent topics such as “How to Foster an Inclusive Environment”
and “Creating Psychological Safety at Work.”• Bringing awareness to the diverse backgrounds of our team membersby spotlighting their stories and hosting ad hoc events such as lunches
that celebrate different heritages.

ALLOGENE ENVIRONMENTAL, SOCIAL AND GOVERNANCE REPORT | 12

VALUING OUR PEOPLE

Staying Connected and Informed
In early 2019, we launched Allogene’s internal communications application

We host regular Town Hall meetings, offering the latest Allogene updates

that we call “The CarT.” This platform enables two-way communication andand taking questions through an anonymous online Q&A tool.

interaction across all employees at all locations. Regular content on thisplatform includes messages
from our CEO; “SLT Top 3”
posts by our senior leaders,
in which they share their

Our Senior Leadership Team (SLT) also host “Ask Us Anything” events,
which are informal Q&A sessions to give employees the opportunity to ask
any question they may have about Allogene, the industry, or whatever ison their minds.

top three priorities for the

It is our strong belief that bringing employees together regularly will foster

quarter; employee

our One Allogene culture – especially the trust, candor, thoughtful decision

recognition; event

making and efficient collaboration that are strengthened by teamannouncements; Human

camaraderie and in-person interaction – and is inherent to Allogene’s

Resources (HR) updates;

success. In 2022 Allogene implemented a new hybrid work policy, in whichphotos from the Allogene

most employees are expected to work onsite at least three days per week.

community; and safety,

We also host frequent in-person and virtual social and wellness events,

legal, compliance, andincluding Trivia Nights, March Madness and holiday parties, yoga classes andcybersecurity updates

meditation sessions, to maintain our culture.

and reminders.
In 2022, we revamped our employee intranet, “AlloNet,” to ensure
employees can quickly access current information regarding benefits andwellness, learning and development, company culture, policies, andinitiatives with a modern interface for a user-friendly experience.

IT IS OUR STRONG BELIEF THAT BRINGINGEMPLOYEES TOGETHER REGULARLY WILL FOSTEROUR ONE ALLOGENE CULTURE ...

ALLOGENE ENVIRONMENTAL, SOCIAL AND GOVERNANCE REPORT | 13

VALUING OUR PEOPLE

Safety in the Workplace
One key aspect of our One Allogene culture is the principle that “We Aim
for Excellence and Give it Our All,” and that includes prioritizing safety.

We also have a task-based safety training program that ensures

Ingrained in that behavior is the tenet to follow all health and safety

staff are assigned the appropriate training to understand how topolicies and procedures and prioritize the safety of our team.

safely perform their duties. At minimum, all workers are required to

To maintain a safe and healthy workplace, we have a comprehensive
Environment, Health and Safety (EHS) program that focuses on key risk
mitigation programs that identify, assess, and correct hazards. In
addition, we have emergency response teams at each location that are
responsible for sweeping the Allogene buildings during an emergency

complete New Hire Orientation which includes training on:• Injury and Illness
Prevention Program• Hazard Communication• Fire Prevention• Emergency Action Plan
• Security Program

evacuation to account for all employees and providing first-aid care forfellow colleagues in the event of injury, exposure, or medical emergency.
An external third party conducts an audit every three years to ensure the

Furthermore, access to controlled areas is dependent on a worker’s role,

program is adhering to safety and environmental regulations. In 2022,

training, and business need, a policy that protects both employee safety

this audit was completed without any significant findings.

and laboratory integrity. Additional trainings are assigned to employees
based on their job duties and may include topics such as bloodborne
pathogens, hazardous waste management, electrical safety, and control of

IN 2022, ALLOGENE HAD A RECORDABLEINCIDENT RATE OF 1.28, INCLUDING AN INJURYRATE OF ZERO ...

hazardous energy.
In 2022, Allogene had a recordable incident rate of 1.28, including
an injury rate of zero, and no Occupational Health & Safety (OH&S)
related deaths.

ALLOGENE ENVIRONMENTAL, SOCIAL AND GOVERNANCE REPORT | 14

VALUING OUR PEOPLE

EHS Governance and Engaging Employees
In collaboration with Allogene’s EHS team, each site has a cross-functional
EHS committee that is comprised of members across different functions
and different levels in the organization.

Each EHS committee is supervised by siteleadership teams that review safety metrics,
incidents, and EHS committee performance on atleast a quarterly basis. In 2022, we began including
our SLT in a new safety inspection process to increase

The EHS committees review safety metrics to identify potential trends,

accountability and engagement. At Allogene, we

review and analyze incidents to provide feedback on action plans, andconduct monthly safety inspections of all our

drive EHS initiatives tobuildings and strive to close out all corrective

increase awareness andactions on time. All safety incidents are

improve performance. In

posted to The CarT so every Allogene

2022, the site committees

employee is aware and can learn fromcame together to develop athese incidents.

comprehensive safety andsecurity video featuring
our employees, to train our
staff on best practices toensure a safe and secure
work environment for all. All
South San Francisco EHS Committee

employees are required totake this training.

11

ALLOGENE ENVIRONMENTAL, SOCIAL AND GOVERNANCE REPORT | 15

RECRUITING, DEVELOPING
AND RETAINING TALENT
Successful execution of our recruitment strategy is dependent on

During the interview process, we encourage consistent questions to

attracting, developing and retaining our employees. Our leadership in the

mitigate unconscious bias and utilize behavioral interviewing techniques

field of allogeneic cell therapy and our bold culture have allowed us toto assess experience, skills, knowledge and behaviors. We also makerecruit a talented workforce.

concerted efforts to compile a diverse panel of interviewers when

Recognizing the value of our best-in-class workforce, in 2022 we hired
Allogene’s first Chief People Officer, a role aimed at attracting new talentand retaining and cultivating our existing team as Allogene scales
operations for the next stage of growth. We also implemented a corporate
goal around attrition – to decrease our attrition rate by 15% – which we
well exceeded by decreasing our attrition rate by over 50% year over year.

assessing each candidate to further reinforce the importance of gaining
perspectives from people with different backgrounds, thoughts andexperience. Our focus is on hiring candidates that are a “culture add”
rather than a “culture fit.” We believe it to be critical that this is viewed
both ways, meaning that the candidate is also interviewing Allogene.
Our recruitment efforts are designed to diversify our workforce,increase opportunities to underrepresented minorities and benefit the
local community.

2022

115

new employees

70

Average number ofdays to hire

80%of candidates
accepted our offers

We are in a highly competitive field and geographic region for life sciencetalent and historically have faced proportionally higher attrition among
our research, development and technical operations teams than our
general and administrative teams. While our voluntary attrition rate
declined to 12% in 2022, we believe we will continue to face significant
competition for life science talent.

ALLOGENE ENVIRONMENTAL, SOCIAL AND GOVERNANCE REPORT | 16

RECRUITING, DEVELOPING AND RETAINING TALENT

Compensation & Benefits

Along with our One Allogene culture, we offer an attractive
total compensation package, which helps recruit and retain ourtalent. Our compensation package includes market-competitive
pay, broad-based stock grants and a 401(k) plan with companymatching benefits. Other highlights and benefits include:

Recognizing the importance of employee wellness, in
2022 we:• Office closures at year-end and the week of July 4th.

• Enhanced our benefits offerings and health savings subsidies,• “No Meeting” Friday afternoons.
• Lunch program subsidized by Allogene.
• Reimbursements for reasonable and necessary business expenses.
• Mental health and wellness support, such as through our
Employee Assistance Program that includes a 24-hour, 7-day free• Implemented new vacation and sick time policies, granting
employees 10 sick days to be used to promote physical andmental wellbeing.
incorporating COBRA care for any employee who transitions
from Allogene.

• Launched a new wellness platform, which supports employees’
physical and mental wellbeing.

• Held four company-wide workout challenges.

emotional-support help line, guided meditations and exercise,• Hosted onsite flu shot clinics.

company-wide wellness competitions, and reimbursements for• Hosted a biometrics wellness screening, in which employees

gym memberships.

• Paid leave programs, including for medical leave, dependent careand new parents.

had the opportunity to be privately screened for total cholesterol,
triglycerides and glucose levels and other biometrics such as
blood pressure and body mass index (BMI).

ALLOGENE ENVIRONMENTAL, SOCIAL AND GOVERNANCE REPORT | 17

RECRUITING, DEVELOPING AND RETAINING TALENT

We base components and ranges of compensation on market andWe believe that the option exchange furthers long-term stockholder valuebenchmark data, striving to pay all employees equitably within aby increasing our ability to retain experienced and talented employees,

reasonable range, taking into consideration factors such as role; internalaligning the interests of these individuals more fully with the interests ofequity; job location; relevant experience; and individual, department andour stockholders, improving morale among our employees, andcompany performance.

reinvigorating a culture where equity compensation is a key component of

In 2022, given market conditions for the biotech industry and with

our overall compensation package.

approval of our shareholders, we were a standout in our industry by

We conduct an annual third-party benchmark analysis of our compensation

offering employees a voluntary stock option exchange program, in which

practices and structures and in 2022, again confirmed that our compensation

eligible employees who held stock options with an exercise price overprogram is equitable. It is our policy to review and take action if we identify$18.00 and granted prior to December 31, 2021 were given the ability toemployees with unjustified pay gaps. We conduct and report on our pay

exchange these options for lower-priced options. We offered a 1:1

equity analysis to our Compensation Committee on an annual basis.

exchange and options were reset to a three-year vesting term. Certain
senior executives, directors, and consultants were excluded fromparticipating in this program. 96% of eligible employees participated.

Our employees are eligible for annual bonuses that are tied to bothindividual and company performance to foster a merit and performancebased culture. Employees are also eligible for annual equity grants.
We offer an attractive Employee Stock Purchase Program, which allows

IN 2022 ... WE WERE A STANDOUT IN OUR INDUSTRYBY OFFERING EMPLOYEES A VOLUNTARY STOCKOPTION EXCHANGE PROGRAM ...

all employees to purchase Allogene shares twice a year at a 15% discountwith a two-year offering period and lookback provision. This means thatfor each 6-month purchase, the plan will default to the lower of the priceat the purchase date or the price at the beginning of the offering period.
The 15% discount is then applied to the lower price.

.

ALLOGENE ENVIRONMENTAL, SOCIAL AND GOVERNANCE REPORT | 18

RECRUITING, DEVELOPING AND RETAINING TALENT

Career Development

Spot Recognition through Allogene’s Gratitude Lab

We are creating a culture of continuous improvement and one that fosters

At Allogene, we celebrate big and small achievements through an internal

career development. Some highlights:

channel called The Gratitude Lab. Through The Gratitude Lab, employees• Employees create annual Individual Goals that are intended to tie into

can nominate colleagues for spot recognition awards for exhibiting ourdepartment or corporate goals, as well as Individual Development Plans
to outline their own career goals and to provide a basis for development
conversations between employees and their managers.

• Career Ladders clarify the criteria and expectations of each job levelat Allogene. This resource, developed by more than 100 employees at
Allogene, supports managers in their career development discussions
with direct reports and provides transparency to employees aroundpromotion criteria.

• Mid-year and year-end performance reviews include discussions
about goals and how employees demonstrate and model core
One Allogene behaviors.

One Allogene core behaviors and for going above and beyond expected
job responsibilities. The Gratitude Lab nominations are shared with all
employees on The CarT to bring awareness to the great work being doneby our teams.

265

Gratitude Lab spot bonuses were awarded in 2022

Taking a StandIn 2022, Allogene employees recognized the crisis in Ukraine and raised

To further their own professional development, employees can use amoney to donate to children with cancer in the war-stricken country. In

variety of learning and development resources, including a catalog of overwhat represents One Allogene at its core and central to our mission of

1,000 offerings provided by a leading HR solutions provider, as well as live

being leaders in every aspect, these donations were personally matchedtrainings offered throughout the year.

by our CEO and Executive Chairman.

ALLOGENE ENVIRONMENTAL, SOCIAL AND GOVERNANCE REPORT | 19

PRIORITIZING ENVIRONMENTALSUSTAINABILITY

ALLOGENE ENVIRONMENTAL, SOCIAL AND GOVERNANCE REPORT | 20

PRIORITIZING ENVIRONMENTAL SUSTAINABILITY

The well-being of our communities is enriched by a safe, clean and healthy environment.
We aim to reduce our environmental footprint and impact through corporate initiatives andin compliance with applicable laws and regulations.
The objectives of our approach to minimize environmental
impact are to:B e an environmentally responsible corporate citizen
 onitor consumption of resources used by Allogene inM
our operations
 ducate our employees and provide channels forE
employees to create environmental awareness andcontribute to our efforts
 onitor and continually improve our measures toM
use resources more efficiently and minimize adverse
environmental effects.

ALLOGENE ENVIRONMENTAL, SOCIAL AND GOVERNANCE REPORT | 21

PRIORITIZING ENVIRONMENTAL SUSTAINABILITY

The Facility of the Future: Cell Forge 1
Cell Forge 1 (CF1) is Allogene’s state-of-the-art cellmanufacturing facility in Newark, California and the homeof the next revolution in CAR T cell products. Our 136,000
square foot facility was designed and constructed from theground-up to optimize energy performance and efficiency.
This includes the use of low-emitting materials, segregation and recyclingof construction waste, and selection of energy-efficient utility equipment.
With construction completed in 2020, it is a high-profile example of ourcommitment to environmental sustainability.
In 2022, the facility earned LEED Gold certification for its environmentallyfriendly design and construction.
CF1 is a fully-electric facility with power that is supplied by 2,400 solar
panels installed on the roof, batteries charged by the solar panels,
and power supplied by our utility company, which comes from 100%
renewable solar and wind power.
The building’s energy efficient design and construction includes:• Heat Pump technology for heating and cooling• Dedicated outdoor air system• Hot Aisle Containment (HAC)• Natural light or LED lighting throughout• Energy metering and performance monitoring, allowing for continued
energy reduction efforts

ALLOGENE ENVIRONMENTAL, SOCIAL AND GOVERNANCE REPORT | 22

PRIORITIZING ENVIRONMENTAL SUSTAINABILITY

Current Initiatives to Reduce Environmental Impact
We have several ongoing efforts to protect the environment. These include
sustainability initiatives to reduce greenhouse gas emissions by utilizing
renewable energy and reducing energy demand by reviewing our systems• Water-use reduction devices on all bathroom faucets and toilets• Dispensers for snacks and compostable utensils that reduce packaging
and container waste• Compostable materials used for all crockery at Allogene sites and eventsfor energy efficiency. CF1 uses 100% carbon-free, renewable energy, and• Removal of plastic bottle drinking options

our sites in South San Francisco, California utilize electric power from

• Reusable cups and mugs provided to all new employees

sources that are 50% renewable.
In 2022, we celebrated Earth Week at Allogene and ran a comprehensive• Recycling disposable face masks at all sites• Implementing a new program to sanitize our safety glasses to enablecampaign to encourage employees to prioritize sustainability. Aside fromreuse as part of our standard laboratory operation practices for the labs

spotlighting Allogene’s sustainability initiatives, our EHS team and our

located in our headquarter facility

employees shared sustainable habits on our internal communications
platform, and employees were eligible for sustainable prizes, like acomposter, for their participation.
Other sustainability initiatives include:• Electric vehicle charging stations• A $50-per-month reimbursement for employees taking public transit• Subsidized passes for employees who take commute.org shuttles in
the Bay Area
• Recycling/composting, including signage at waste containers to help
employees understand what can be composted and what can berecycled to divert waste from landfill

Our CF1 facility had one environmental notice of violation in 2022 but iscompleting infrastructure remedial upgrades to the facility.

Our Focus for the Future
Our commitment to environmental sustainability is an ongoing, evolving
development. To assist in its evolution, we plan to collect and analyze
relevant data to help us understand our environmental impact and help us
improve going forward.

ALLOGENE ENVIRONMENTAL, SOCIAL AND GOVERNANCE REPORT | 23

PURSUING THE HIGHEST
ETHICAL STANDARDSAllogene’s Board and Corporate Governance
ESG oversight starts with Allogene’s Board of Directors. In December

Our cross-functional ESG Working Group assists the NCGC in fulfilling its

2021, our Board and Nominating and Corporate Governance Committee

oversight responsibilities with respect to ESG. The Group is comprised ofapproved an amendment to the Committee’s charter for explicit oversightcolleagues from the following departments:of ESG matters at Allogene. The Committee also has responsibility forreporting to the Board periodically on ESG matters.

Board Diversity
At Allogene, we strive to achieve Board diversity in the broadest sense by•C linical Operations•L egal•E
 nvironmental, Health and Safety (EHS)•Q uality•H uman Resources•S upply Chain• Investor Relations

including persons diverse in gender, ethnicity, age, experience andgeographic location. Our Board is comprised of healthcare investors,
Board ofDirectors

academics, pharma industry veterans and biotech entrepreneurs, many ofwhom have extensive experience in cell therapy. In 2022, the Board

Allogene’s Board of
Directors oversees allpolicies and strategy.

appointed an additional director from an underrepresented community.
Two other directors joined our Board in 2021, and the remainder joined
our Board in 2018. The eleven directors range in age from 46 to 80. Three
directors self-identify as female, two self-identify as Asian and one self-

Audit
Committee

Compensation
Committee

Nominating
and Corporate
GovernanceCommittee

identifies as African American.
Our Nominating & Corporate Governance Committee (NCGC), which
oversees Allogene’s ESG initiatives at the Board level, reviewed ESG

SeniorLeadershipTeampractices at multiple NCGC meetings in 2022.
ESG Working
Group

International andBusiness Development
Oversight Committee

The Senior Leadership Teamoversees the ESG Working
Group and reports theirprogress to the Nominating& Corporate GovernanceCommittee.
The ESG Working Group is
responsible for executionof Allogene’s ESG strategy.

ALLOGENE ENVIRONMENTAL, SOCIAL AND GOVERNANCE REPORT | 24

PURSUING THE HIGHEST ETHICAL STANDARDSBusiness Ethics and Human Rights
We have a set of policies that reinforce our commitment to ethical andWe recognize our responsibility to develop a company culture that

responsible conduct. At the center is our Code of Business Conduct andadvocates respect for all human rights and avoids complicity in human

Ethics. Other key policies include our Diversity, Equity and Inclusion

rights abuses. Our Human Rights Policy supports the principles outlined in

Policy; Workplace Harassment, Discrimination and Retaliation Prevention

the UN Guiding Principles on Business and Human Rights and addresses

and Complaint Procedures Policy; and Open Door Policy.

human rights matters relating to the workplace, environment, clinical trials

We have also implemented a Human Rights Policy, which is discussed in
more detail below. All of these policies are available on our internal andexternal websites.

and its supply chain. In 2022, we distributed our Human Rights Policy to
our Partners, and it is now incorporated into all new contracts through ourPurchase Order Terms and Conditions.

Topics covered in the Allogene Code include• Honest and Ethical Conduct• Insider Trading• Corporate Opportunities• Legal and Regulatory Compliance• International Business Laws

• Financial Integrity and• Diversity, Equity, Inclusion and• Antitrust

Anti-Harassment

Public Reporting• Environmental Compliance• Fair Dealing• Conflicts of Interest• Gifts and Entertainment• Protection and Proper
Use of Corporate Assets• Confidentiality

ALLOGENE ENVIRONMENTAL, SOCIAL AND GOVERNANCE REPORT | 25

PURSUING THE HIGHEST ETHICAL STANDARDS

Training
Our employees receive mandatory quarterly compliance training, periodic
written notices on compliance matters and are offered a variety of otherresources and trainings to encourage diversity, equity and inclusion,
anti-harassment and compliance with laws. In addition, the SLT undergoes
annual training by external counsel on compliance matters.

Reporting Resources and Non-Retaliation
If someone at Allogene has a good faith complaint regarding a possible
violation of law or policy, we expect them to report that complaint
promptly. We offer a 24/7 whistleblower hotline managed by a third party
to allow for anonymous reporting. Third parties, including consultants andvendors, may also make a good faith complaint. Employees areencouraged to report non-compliance without fear of any form of
retaliation. We will take prompt disciplinary action against any employee
who retaliates, up to and including termination of employment.
Our Board has designated our General Counsel as our Compliance Officer,
who is required to follow certain procedures upon the receipt of any report
alleging violation of company policies. Employees who do not feel
comfortable speaking with our Compliance Officer can contact our Chief
Financial Officer, Chief Executive Officer or the chair of the Board of
Directors’ Audit Committee.

ALLOGENE ENVIRONMENTAL, SOCIAL AND GOVERNANCE REPORT | 26

PURSUING THE HIGHEST ETHICAL STANDARDSClinical Trials

Allogene recognizes the importance of publishing the results of clinical

Allogene is a clinical-stage company and we do not currently

development of new medicines, enables avoidance of duplicative trials,

commercialize or market any prescription biopharmaceutical products.

and builds public trust by fulfilling our obligations to participants andWe design and conduct our clinical trials with high standards per

allowing others to analyze the data. More importantly, Allogene believes

International Conference on Harmonization of technical requirements forthat the goal of conducting a clinical trial is to benefit patients and making

registration of pharmaceuticals for human use and Good Clinical Practicethe results of our trials available for patients and their physicians to(ICH-GCP). We follow the ICH-GCP standards, which are consistent withdetermine appropriate treatments is a significant step to serving patients.

global ethical standards that have their origin in the World Medical

Allogene is committed to publishing the results of our clinical trials after

Association’s Declaration of Helsinki, to ensure that ethical and scientificcompletion of the trial in accordance with regulatory requirements.

qualities are maintained throughout our trials to generate results that are
reliable and valid.
Prior to commencing any clinical trial, we must meet strict rules set forth

trials. At a high level, publication encourages innovation and theAllogene publishes results of its research and development at various
timepoints, as appropriate. These are available on the Allogene website,
under Scientific Publications.

by the U.S. Food and Drug Administration (FDA), including submitting an
Investigational New Drug (IND) application for clearance by the FDA.
In addition, an independent Institutional Review Board (IRB) for eachclinical trial site must review and approve the plan for any clinical trial
before it commences at that site. Upon trial initiation, we takeresponsibility for ensuring that the clinical trial is conducted in accordancewith an investigational plan and protocol that is in conformity with all
regulatory requirements and approvals.

Intellectual Property
Allogene sponsors research at several academic research centers to help
advance innovations from the academic laboratory into translatable products/
services that can provide greater social benefit. In addition to funding,
Allogene may share its proprietary materials and know-how to collaborate
with these non-profit institutions to further their research initiatives.
Separately, Allogene patent applications are published on the USPTO andWIPO websites in accordance with applicable publication requirements.

ALLOGENE ENVIRONMENTAL, SOCIAL AND GOVERNANCE REPORT | 27

PURSUING THE HIGHEST ETHICAL STANDARDS

Product Quality and Patient Safety

Supply Chain and Partners

Our product candidates are subject to extensive regulations focused on

We rely on a network of business partners to help accomplish our goal toquality and safety. All product candidates must be manufactured pursuant

successfully treat cancer patients. This network includes upstream andto current good manufacturing practices (cGMP) requirements, using

downstream supply chain through our partners,

qualified equipment and materials. Allogene’s Operations Technology

service providers, suppliers and contractors

Department has implemented a number of procedures and processes to(Partners). We expect our Partners toassure appropriate cGMP manufacturing and product release.

exercise responsible and ethical

We have an internal Safety Review Board that manages the safety of
Allogene’s product candidates and communication of safety matters withkey stakeholders such as regulators, investigators and clinical sites,
including the sites’ IRB. We may also engage an independent group ofqualified experts organized by Allogene, known as a data safety
monitoring board (DSMB), to provide an independent review of clinical
trial data at designated checkpoints and advise us regarding the continuing
safety of clinical trial subjects. Through its regular review of data, the DSMB

practices and to maintaincompliance with all legal andregulatory requirements. We
distribute our Human Rights
Policy to our Partners to ensure
our intentions around environmental
responsibility, labor practices, diversity,
equity and inclusion are clear.

may recommend changes to the trial design based on emerging safetyconcerns, including termination of the trial if it identifies an unacceptablesafety risk for subjects. In 2022, a DSMB was established for our Phase 2
allogeneic CAR T trials.

[ALLOGENE HAS] AN INTERNAL SAFETY REVIEW BOARD THAT MANAGES THE SAFETY OF ALLOGENE’S
PRODUCT CANDIDATES AND COMMUNICATION OF SAFETY MATTERS WITH KEY STAKEHOLDERS ...

ALLOGENE ENVIRONMENTAL, SOCIAL AND GOVERNANCE REPORT | 28

PURSUING THE HIGHEST ETHICAL STANDARDSManaging Cybersecurity Risk
At Allogene, we are committed to maintaining a secure information

online cybersecurity training course. Allogene’s IT Security team shares

technology environment. We have amended our Audit Committee chartermonthly awareness communications and provides periodic reminders

to include oversight of cybersecurity. We follow the guidance of theregarding cybersecurity. Lastly, we run a simulated phishing campaign with

National Institute of Standards and Technology (NIST) and rely on the fiveprizes to incentivize team members to increase recognition of potentialfunctions of the NIST framework, as illustrated below.

security threats and reporting.

At Allogene, we believe cybersecurity starts with a trained and educated

In 2022, Allogene had no material cybersecurity breaches toworkforce. Each year, employees are required to complete a mandatory

our knowledge.

Identify

Protect

Detect

We identify threats
through various means,including through employee
training, establishing new
cyber policies andstandards, and performing
ongoing assessments ofour programs.

We work to protect all of
our confidential data withsecure firewalling for lab andmanufacturing systems to
mitigate risk, an advanced
email security solution,
restriction of USB usage
on laptops to reduce data
loss and strict permissions
to protect network shares.

We are continuously
monitoring and detecting
threats with 24-hour rapid
monitoring, quarantine ofany compromised device
and frequent operational
review of cyber risks
and trends.

Respond
We have established arobust incident response
plan for our IT team toutilize and have partneredwith a reputablecybersecurity partner
for response.

Recover
We have a recovery
system in place toensure critical lab andmanufacturing systems
are backed up andrecoverable where
possible.

Important legal information
Statements in this report that are not statements of historical fact are forward-looking statements that involve a number of risks and uncertainties.
Such forward-looking statements may be identified by words such as believe, goal, plan, potential, may, will, intend, expect, strive, seek, and design,
and include, among other things, statements about Allogene’s mission, plans, goals, assets, and programs. For such statements, Allogene claims theprotection of the Private Securities Litigation Reform Act of 1995. Actual events or results may differ materially from Allogene’s expectations. Factors that
could cause actual results to differ materially from the forward-looking statements are disclosed in Allogene’s filings with the Securities and Exchange
Commission (SEC), including under the Risk Factors heading of Allogene’s most recently filed Annual Report on Form 10-K or Quarterly Report on Form
10-Q. These forward-looking statements represent Allogene’s judgment as of the time this report was first published. Allogene disclaims any intent or
obligation to update these forward-looking statements, other than as may be required under applicable law.